therapeutic targeting bet bromodomain proteins castration-resistant prostate cancer
men develop metastatic castration-resistant prostate cancercrpc invariably succumb disease progression crpc androgen ablation therapy predominantly driven deregulated rogen receptor ar signalling- despite success recently approved therapies targeting ar signalling abiraterone- second generation anti-androgens including mdv3100 also known enzalutamide durable responses limited presumably owing acquired resistance recently jq1 i-bet762 two selective small-molecule inhibitors target amino-terminal bromodomains brd4 shown exhibit anti-proliferative effects range malignancies- show ar-signalling-competent human crpc cell lines preferentially sensitive bromodomain extraterminal bet inhibition brd4 physically interacts n-terminal domain ar can bedisrupted jq1refs like direct ar antagonist mdv3100 jq1 disrupted ar recruitment target gene loci contrast mdv3100 jq1 functions downstream ar potently abrogated brd4 localization ar target loci ar-mediated gene transcription including induction tmprss2-erg gene fusion oncogenic activity vivo bet bromodomain inhibition efficacious direct ar antagonism crpc xenograft mouse models taken together studies provide novel epigenetic approach concerted blockade oncogenic drivers advanced prostate cancer
